{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"Progression-free survival (PFS) defined as time from first dose of study drug to date of first tumor progression or death due to any cause","groups":[{"description":"50 mg BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.","id":"OG000","title":"BION-1301 50 mg Q2W"},{"description":"150 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG001","title":"BION-1301 150 mg Q2W"},{"description":"450 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG002","title":"BION-1301 450 mg Q2W"},{"description":"1350 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG003","title":"BION-1301 1350 mg Q2W"},{"description":"2700 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG004","title":"BION-1301 2700 mg Q2W"},{"description":"1350 mg BION-1301 will be administered as an IV infusion once per week for up to 8 weeks, followed by dosing once every 2 weeks.","id":"OG005","title":"BION-1301 1350 mg QW*8W->Q2W"}],"populationDescription":"Study was terminated early and Phase 2 did not enroll. Progression-free survival was not assessed.","reportingStatus":"POSTED","timeFrame":"Approximately 30 months","title":"Progression-Free Survival (Phase 2)","type":"PRIMARY"}